Agomab Therapeutics (AGMB) Intangibles (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Intangibles of $23.4 million for Q4 2025, up 8.93% year-over-year from $21.5 million in Q4 2024, and up 8.93% quarter-over-quarter from $21.5 million in Q4 2024.
Agomab Therapeutics (AGMB) Intangibles (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Intangibles history runs 2 years deep, the most recent figure standing at $23.4 million for Q4 2025.
- In Q4 2025, Intangibles rose 8.93% year-over-year to $23.4 million; the TTM figure through Dec 2025 stood at $23.4 million (up 8.93% YoY), while the FY2025 annual figure was $23.4 million, up 7.55% from the prior year.
- Intangibles for Q4 2025 stood at $23.4 million, up from $21.5 million in the prior quarter.
- The five-year high for Intangibles was $23.4 million in Q4 2025, with the low at $21.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Agomab Therapeutics | 7.07 Mn | -250.51 Mn | - | 23.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.41 Mn |
| Dec 31, 2024 | 21.49 Mn |